Lymph node targeting strategy using a hydrogel sustained-release system to load effector memory T cells improves the anti-tumor efficacy of anti-PD-1
Source abstract
Abstract
Communication between tumors and lymph nodes carries substantial significance for antitumor immunotherapy. Remodeling the immune microenvironment of tumor-draining lymph nodes (TdLN) plays a key role in enhancing the anti-tumor ability of immunotherapy. In this study, we constructed a biomimetic artificial lymph node structure composed of F127 hydrogel loading effector memory T (TEM) cells and PD-1 inhibitors (aPD-1). The biomimetic lymph nodes facilitate the delivery of TEM cells and aPD-1 to the TdLN and the tumor immune microenvironment, thus realizing effective and sustained anti-tumor immunotherapy. Exploiting their unique gel-forming and degradation properties, the cold tumors were speedily transformed into hot tumors via TEM cell supplementation. Meanwhile, the efficacy of aPD-1 was markedly elevated compared with conventional drug delivery methods. Our finding suggested that the development of F127@TEM@aPD-1 holds promising potential as a future novel clinical drug delivery technique. STATEMENT OF SIGNIFICANCE: F127@TEM@aPD-1 show unique advantages in cancer treatment. When injected subcutaneously, F127@TEM@aPD-1 can continuously supplement TEM cells and aPD-1 to tumor draining lymph nodes (TdLN) and the tumor microenvironment, not only improving the efficacy of ICB therapy through slow release, but also exhibiting dual regulatory effects on the tumor and TdLN.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Immunotherapy and Immune Responses · Cancer Immunotherapy and Biomarkers · Immune Cell Function and Interaction
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (41)
Show source-provided references
1. Combination cancer immunotherapies: emerging treatment strategies adapted to the tumor microenvironment10.1126/scitranslmed.abo3605 ↗
2. The foundations of immune checkpoint blockade and the ipilimumab approval decennial10.1038/s41573-021-00345-8 ↗
3. Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis10.1016/S1470-2045(21)00333-8 ↗
4. Enfortumab vedotin in previously treated advanced urothelial carcinoma10.1056/NEJMoa2035807 ↗
5. Treatment-Related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis10.1001/jamaoncol.2019.0393 ↗
6. Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma10.1093/annonc/mdw160 ↗
7. Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1/PD-L1 blockade-sensitive mouse models10.1136/jitc-2019-000400 ↗
8. Radiotherapy and immunotherapy: open questions and future strategies10.1016/j.trecan.2021.10.003 ↗
9. The developing landscape of combinatorial therapies of immune checkpoint blockade with DNA damage repair inhibitors for the treatment of breast and ovarian cancers10.1186/s13045-021-01218-8 ↗
10. Synergy of nanodiamond-doxorubicin conjugates and PD-L1 blockade effectively turns tumor-associated macrophages against tumor cells10.1186/s12951-021-01017-w ↗
11. Codelivery of Anti-PD-1 antibody and paclitaxel with matrix metalloproteinase and pH dual-sensitive micelles for enhanced tumor chemoimmunotherapy10.1002/smll.201906832 ↗
12. Neoantigen-specific CD4(+) T cells in human melanoma have diverse differentiation states and correlate with CD8(+) T cell, macrophage, and B cell function10.1016/j.ccell.2022.03.006 ↗
13. Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids10.1016/j.cell.2018.07.009 ↗
14. Targeting cancers through TCR-peptide/MHC interactions10.1186/s13045-019-0812-8 ↗
15. Reprogramming of sentinel lymph node microenvironment during tumor metastasis10.1186/s12929-022-00868-1 ↗
16. The lymphatic vasculature in the 21(st) century: novel functional roles in homeostasis and disease10.1016/j.cell.2020.06.039 ↗
17. Tumor invasion in draining lymph nodes is associated with Treg accumulation in breast cancer patients10.1038/s41467-020-17046-2 ↗
18. Tumor draining lymph nodes, immune response, and radiotherapy: towards a revisal of therapeutic principles10.1016/j.bbcan.2022.188704 ↗
19. Reversing T-cell exhaustion in cancer: lessons learned from PD-1/PD-L1 immune checkpoint blockade10.1158/2326-6066.CIR-21-0515 ↗
20. Dynamic CD8(+) T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes10.1016/j.cell.2023.02.021 ↗
21. CD8(+) T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor10.1016/j.immuni.2022.12.002 ↗
22. Central memory and effector memory T cell subsets: function, generation, and maintenance10.1146/annurev.immunol.22.012703.104702 ↗
23. The function and dysfunction of memory CD8(+) T cells in tumor immunity10.1111/imr.12657 ↗
24. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions10.1038/44385 ↗
25. An injectable thermosensitive Pluronic F127/hyaluronic acid hydrogel loaded with human umbilical cord mesenchymal stem cells and asiaticoside microspheres for uterine scar repair10.1016/j.ijbiomac.2022.07.161 ↗
26. Nanodefensin-encased hydrogel with dual bactericidal and pro-regenerative functions for advanced wound therapy10.7150/thno.53089 ↗
27. An injectable gelatin/sericin hydrogel loaded with human umbilical cord mesenchymal stem cells for the treatment of uterine injury10.1002/btm2.10328 ↗
28. Exosomes: the next generation of endogenous nanomaterials for advanced drug delivery and therapy10.1016/j.actbio.2018.12.045 ↗
29. Facile fabrication of biocompatible gelatin-based self-healing hydrogels10.1021/acsapm.9b00143 ↗
30. The primordial differentiation of tumor-specific memory CD8(+) T cells as bona fide responders to PD-1/PD-L1 blockade in draining lymph nodes10.1016/j.cell.2022.09.020 ↗
31. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance10.1146/annurev-pathol-042020-042741 ↗
32. Intratumoral Anti-PD-1 nanoformulation improves its biodistribution10.1021/acsami.1c22479 ↗
33. Delivery routes matter: safety and efficacy of intratumoral immunotherapy10.1016/j.bbcan.2021.188526 ↗
34. Intratumoral IL12 mRNA therapy promotes TH1 transformation of the tumor microenvironment10.1158/1078-0432.CCR-20-0472 ↗
35. Temperature sensitive liposome based cancer nanomedicine enables tumour lymph node immune microenvironment remodelling10.1038/s41467-023-38014-6 ↗
36. Thermosensitive hydrogel releasing nitric oxide donor and anti-CTLA-4 micelles for anti-tumor immunotherapy10.1038/s41467-022-29121-x ↗
37. Head and neck squamous cell carcinoma10.1038/s41572-020-00224-3 ↗
38. The changing therapeutic landscape of head and neck cancer10.1038/s41571-019-0227-z ↗
39. Gupta · Oral Oncol. · 2022 · 12410.1016/j.oraloncology.2021.105642 ↗
40. Neck dissections based on sentinel lymph node navigation versus elective neck dissections in early oral cancers: a randomized, multicenter, and noninferiority trial10.1200/JCO.20.03637 ↗
41. Immunotherapy goes local: the central role of lymph nodes in driving tumor infiltration and efficacy10.3389/fimmu.2021.643291 ↗